Bladder Cancer Weekly

October 14, 2024

Videos

Peer-to-Peer Clinical Conversations

UGN-101 in Upper Tract Urothelial Cancer: Real-World Data Analysis - Joseph Jacob

Joseph Jacob

Sam Chang interviews Joseph Jacob about a registry trial examining the effectiveness of Jelmyto (UGN-101) in treating ureteral tumors.

EV-302 Correlative Analysis Sheds Light on Biomarker Analysis in Treatment of Urothelial Cancer - Thomas Powles

Thomas Powles

Thomas Powles discusses the EV-302 trial data, focusing on biomarker analyses for enfortumab vedotin (EV) plus pembrolizumab in urothelial cancer.

Beyond the Abstracts

If Not Now, Then When? The Need for New Evidence in the Robotic Management of Upper Tract Urothelial Carcinoma - Beyond the Abstract

Novel Therapeutic Regimens in Previously Untreated Metastatic Urothelial Carcinoma: A Systematic Review and Bayesian Network Meta-Analysis - Beyond the Abstract

Conference Coverage

ESMO 2024: Invited Discussant: JCOG1019, TOMBOLA, and SunRISe-4

ESMO 2024: TAR-200 plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Patients with Muscle-Invasive Bladder Cancer Who Are Ineligible for or Refuse Neoadjuvant Cisplatin-Based Chemotherapy: Interim Analysis of SunRISe-4

ESMO 2024: Empowering Bladder Cancer Care Integrating Patient Preferences and Voices

ESMO 2024: Histology Subtypes (variants) of Bladder Cancer

ESMO 2024: JCOG1019 Phase III Study Comparing the Effectiveness of Watchful Waiting and Intravesical BCG in Patients with High-grade pT1 Bladder Cancer with pT0 on the 2nd Transurethral Resection Specimen

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Analysis of the Application of the Micrometric Substaging System to Predict Recurrence and Progression in a Cohort of Patients with pT1 High-Grade Non-Muscle Invasive Bladder Cancer.

Strategies to Improve Clinical Outcomes and Patient Experience Undergoing Transurethral Resection of Bladder Tumor.

Survival Outcomes in Patients With Muscle-Invasive Bladder Cancer Receiving Neoadjuvant Chemotherapy Stratified by Number of Cycles.

Novel intravesical therapies and delivery systems for the management of bladder cancer.

Predicting response to intravesical BCG in high-risk non-muscle invasive bladder cancer using an artificial intelligence-powered pathology assay: development and validation in an international 12 center cohort.

Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomised Controlled Trial.

Impact of DNA Repair Deficiency in the Evolving Treatment Landscape of Bladder Cancer.

Perioperative Complications and In-Hospital Mortality in Paraplegic Radical Cystectomy Patients.

FGFR Inhibition in Urothelial Carcinoma.

A Single Institution Experience in the Management of Localized Neuroendocrine Carcinoma of the Bladder.

Prognostic Impact of Bone Metastasis in Patients With Metastatic Urothelial Carcinoma Treated With Durvalumab With or Without Tremelimumab in the DANUBE Study.

Management options for node-positive muscle-invasive bladder cancer.

Treatment Preferences and Tradeoffs Among Patients with Locally Advanced or Metastatic Urothelial Carcinoma - Expert Commentary

Early Adjuvant Chemotherapy Improves Survival in Muscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis - Beyond the Abstract

Novel Therapeutic Regimens in Previously Untreated Metastatic Urothelial Carcinoma: A Systematic Review and Bayesian Network Meta-Analysis - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2024 Digital Science Press, LLC